Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: Results from the Dallas Heart Study

American Heart Journal

Volumn 157, Issue 4, 2009, Pages

  de Lemos, James A ^a   McGuire, Darren K ^a   Khera, Amit ^a   Das, Sandeep R ^a   Murphy, Sabina A ^b   Omland, Torbjorn ^c   Drazner, Mark H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CALCIUM; CREATININE;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BIOASSAY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIAGNOSTIC KIT; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOTOMY; PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION; VALVULAR HEART DISEASE;

EID: 62949168054     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.12.017     Document Type: Article

References (33)

1. Devereux R.B., Wachtell K., Gerdts E., et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292 (2004) 2350-2356
2. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
3. Wang T.J., Evans J.C., Benjamin E.J., et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108 (2003) 977-982
4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 327 (1992) 685-691
5. Davies M., Hobbs F., Davis R., et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 358 (2001) 439-444
6. Wang T.J., Levy D., Benjamin E.J., and Vasan R.S. The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening. Ann Intern Med 138 (2003) 907-916
7. Redfield M.M., Jacobsen S.J., Burnett Jr. J.C., et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2003) 194-202
8. de Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
9. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
10. Januzzi Jr. J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 (2005) 948-954
11. McDonagh T.A., Robb S.D., Murdoch D.R., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 351 (1998) 9-13
12. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288 (2002) 1252-1259
13. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 109 (2004) 3176-3181
14. Ng L.L., Loke I.W., Davies J.E., et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol 45 (2005) 1043-1050
15. Groenning B.A., Raymond I., Hildebrandt P.R., et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90 (2004) 297-303
16. Costello-Boerrigter L.C., Boerrigter G., et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 47 (2006) 345-353
17. Galasko G., Lahiri A., Barnes S.C., et al. What is the normal range for N-terminal pro-brain natriuretic peptide? Howe well does this normal range screen for cardiovascular disease?. Eur Heart J (2005)
18. Victor R.G., Haley R.W., Willett D.L., et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 93 (2004) 1473-1480
19. Drazner M.H., Dries D.L., Peshock R.M., et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension 46 (2005) 124-129
20. Hoffmann R., von Bardeleben S., ten Cate F., et al. Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J 26 (2005) 607-616
21. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
22. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 (2002) 976-982
23. Wang T.J., Larson M.G., Levy D., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 90 (2002) 254-258
24. Abdullah S.M., Khera A., Das S.R., et al. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). Am J Cardiol 96 (2005) 1284-1289
25. Luchner A., Burnett Jr. J.C., Jougasaki M., et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 18 (2000) 1121-1128
26. Fahey M.T., Irwig L., and Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 141 (1995) 680-689
27. Punglia R.S., D'Amico A.V., Catalona W.J., et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 349 (2003) 335-342
28. Bottini P.B., Carr A.A., Prisant L.M., et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 8 (1995) 221-228
29. McKie P.M., Rodeheffer R.J., Cataliotti A., et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 47 (2006) 874-880
30. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
31. Kistorp C., Raymond I., Pedersen F., et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293 (2005) 1609-1616
32. Olsen M.H., Hansen T.W., Christensen M.K., et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J (2007)
33. Drazner M.H., and de Lemos J.A. Unexpected BNP levels in patients with advanced heart failure: a tale of caution and promise. Am Heart J 149 (2005) 187-189